Coherus Oncology (CHRS) Times Interest Earned (2013 - 2026)
Coherus Oncology (CHRS) posted Times Interest Earned of -$16.54 for Q1 2026, down 185.8% sequentially from -$5.79 in Q4 2025, and down 218.99% YoY from $13.9 in Q1 2025.
Coherus Oncology (CHRS) Times Interest Earned (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Times Interest Earned for 14 years, with the latest figure at -$16.54 in Q1 2026.
- Quarterly Times Interest Earned fell 218.99% year-over-year to -$16.54 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.88 (up 56.13% YoY) and the FY2025 annual result came in at -$0.49, down 1.74% from the prior year.
- Times Interest Earned retreated to -$16.54 in Q1 2026 per CHRS's latest filing, from -$5.79 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$1.72 in Q4 2022 and troughed at -$21.74 in Q1 2024.
- A 5-year average of -$9.61 and a median of -$7.07 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned sank 431.73% in 2024, then surged 76.15% in 2025.
- Over 5 years, Times Interest Earned stood at -$1.72 in 2022, then tumbled by 276.61% to -$6.49 in 2023, then retreated by 8.96% to -$7.07 in 2024, then advanced by 18.16% to -$5.79 in 2025, then sank by 185.8% to -$16.54 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$16.54, -$5.79, and -$16.64 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -13.92 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.92 |
| Mar 31, 2026 | -16.54 |
| Dec 31, 2025 | -5.79 |
| Sep 30, 2025 | -16.64 |
| Jun 30, 2025 | -15.98 |
| Mar 31, 2025 | -5.18 |
| Dec 31, 2024 | -7.07 |
| Sep 30, 2024 | -16.57 |
| Jun 30, 2024 | -9.76 |
| Mar 31, 2024 | -21.74 |
| Dec 31, 2023 | -6.49 |
| Sep 30, 2023 | -3.12 |
| Jun 30, 2023 | -3.47 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -1.72 |
| Sep 30, 2022 | -10.67 |
| Jun 30, 2022 | -6.69 |
| Mar 31, 2022 | -9.02 |
| Dec 31, 2021 | -6.83 |
| Sep 30, 2021 | -5.46 |